Tissue Regenix Group PLC DermaPure US Clinical data to be presented at SAWC
April 29 2015 - 2:04AM
RNS Non-Regulatory
TIDMTRX
Tissue Regenix Group PLC
29 April 2015
Tissue Regenix Group plc
DermaPure(TM) US Clinical data to be presented at major US Wound
Care Conference
YORK, 29 April 2015 - Tissue Regenix Group plc (AIM:TRX)
("Tissue Regenix" or "the Group"), the regenerative medical devices
company, announces its plans for the Symposium for Advanced Wound
Care (SAWC) Spring meeting being held in San Antonio this week.
Now in its 28(th) year, SAWC is one of the most respected names
in wound care education and brings together over 2000 industry
professionals each year from across the world.
At a breakfast symposium sponsored by Tissue Regenix, we will
demonstrate to attendees the outstanding results of a case series
of 10 US patients treated with DermaPure(TM). The patients involved
in the study had multiple types of wounds with an average size of
12.9cm2 and saw 100% healing in an average time of 6.5 weeks with
1.1 applications.
The presenters are Patti Gary, RN, CWCN, Vice President Clinical
Affairs, Tissue Regenix, San Antonio, TX; Dr. Ardeshir Bayat,
University of Manchester, Manchester Institute of Biotechnology; C.
Jake Lambert, Jr. MD, Bond Clinic, Winter Haven, FL
A poster presentation of the results will also be shown at the
meeting.
Website: http://www.sawc.net/spring/
Antony Odell, CEO of Tissue Regenix Group plc, commented:
"SAWC is a key date in the US wound care professional's calendar
and we are proud to be sharing the positive US clinical experiences
with the attendees. DermaPure(TM) continues to demonstrate
exceptional clinical results in many very difficult wounds that
other types of approach have failed to heal and provides the
potential for dramatic improvements in the clinical outcome of 6.5
million US patients per year."
ENDS
For Further Information
Tissue Regenix Group Plc: +44 19 0443 5176
Antony Odell
Ian Jefferson
Jefferies International Ltd: +44 20 7029 8000
Simon Hardy
Harry Nicholas
Tulchan Communications: +44 207 353 4200
Tom Buchanan
Victoria Huxster
Matt Low
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. The company's patented decellularisation
('dCELL(R)') technology removes DNA and other cellular material
from animal and human tissue leaving an acellular tissue scaffold
which is not rejected by the patient's body which can then be used
to repair diseased or worn out body parts. The potential
applications of this process are diverse and address many critical
clinical needs such as vascular disease, heart valve replacement
and knee repair.
Tissue Regenix was formed in 2006 when it was spun-out from the
University of Leeds. The company commercialises academic research
conducted by our partners around the World.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States- 'Tissue Regenix Wound Care Inc.', as
part of its commercialisation strategy for its dCELL(R) technology
platform.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAIPMRTMBATBMA
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Jul 2023 to Jul 2024